Bakhu Holdings reported multiple financing developments with Phytocyte. The company entered a March 17 MOU for up to $600,000 in interest-free convertible funding tied to restoring regulatory compliance and potential 70% ownership by Phytocyte; that MOU was mutually terminated on April 17. Separately, on April 7, Bakhu signed a Binding Heads of Agreement with Phytocyte for up to $250,000 in interim funding to support creditor payments and compliance work while more detailed documents are prepared.
Agreement 1: Bakhu Holdings Signs MOU With Phytocyte for Up to $600,000 Interest-Free Note, Path to 70% Stake
- Agreement type: Memorandum of Understanding with interest-free convertible funding
- Counterparty: Phytocyte and Inter-M Traders
- Signed / Effective: Mar 17 2026 / same
- Duration / Termination: At will
- Reason: Restore compliance and fund regulatory obligations
Agreement 2: Bakhu Holdings and Phytocyte Terminate March 17 MOU Amid Ongoing Restructuring Efforts
- Agreement terminated: Memorandum of Understanding
- Counterparty: Phytocyte
- Original agreement date: Mar 17 2026
- Termination date: Apr 17 2026
- Termination type: mutual
- Reason: Not disclosed
Agreement 3: Bakhu Holdings Reaches Binding Heads With Phytocyte for Up to $250,000 Interim Funding
- Agreement type: Binding Heads of Agreement for interim funding
- Counterparty: Phytocyte
- Signed / Effective: Apr 7 2026 / same
- Duration / Termination: At will
- Reason: Provide interim liquidity and restore good standing
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.